Osteoporosis Treatment Market

The osteoporosis treatment market is anticipated to grow from US$ 17.17 billion in 2024 to US$ 22.72 billion by 2031, reflecting a projected CAGR of 3.8% from 2025 to 2031.

Analyst Perspective:This report outlines growth opportunities driven by current trends in the osteoporosis treatment market and their expected effects during the forecast period. Osteoporosis can lead to fragile bones, making even minor falls potentially result in fractures, which can significantly impact quality of life. Early detection and treatment can slow or halt the progression of osteoporosis, thereby lowering fracture risk. Consequently, the rising prevalence of osteoporosis heightens the demand for diagnosis, which in turn propels the growth of the osteoporosis treatment market. This condition is predominantly seen in women due to hormonal changes during menopause that affect bone density. Other contributing factors to osteoporosis risk in older adults include rheumatoid arthritis, a family history of the disease, and prolonged use of medications that weaken bones. According to the International Osteoporosis Foundation, among those with osteoporosis, 25% are women and 5% are men aged over 65.

Market Overview:Osteoporosis is a progressive condition that poses a high risk of fractures in men, postmenopausal women, and the elderly. Patients with osteoporosis are particularly vulnerable to fractures in the bones, hips, forearms, spine, and wrists. It is classified as a metabolic disorder that reduces bone mineral density, leading to fractures. Treatment options typically include bisphosphonates, hormone therapy, denosumab, and various nutritional supplements, along with lifestyle changes such as increased physical activity and a diet rich in calcium. Key factors driving the growth of the osteoporosis treatment market include rising healthcare expenditures on research and drug development, as well as growing awareness of available osteoporosis treatments.

Strategic Insights Market Driver: Rising Incidence of Osteoporosis and Lifestyle Changes Fuel Market Expansion

The global prevalence of osteoporosis is on the rise, primarily due to unhealthy lifestyles, poor nutrition, insufficient exercise, low calcium and vitamin D intake, and hormonal imbalances. The International Osteoporosis Foundation reports that osteoporosis leads to over 8.9 million fractures annually, equating to one osteoporotic fracture every three seconds, affecting approximately 200 million women worldwide. The increasing elderly population is another significant factor contributing to the growth of the osteoporosis treatment market. A study published in Labiotech, "Advancements in Osteoporosis Research," indicates that around 10 million Americans have osteoporosis, with approximately 44 million having low bone density, heightening their risk for the disease. The likelihood of developing osteoporosis escalates with age; adults aged 50 and older are at a heightened risk for fractures. In the US, three-quarters of adults aged 65 and older who suffer hip fractures are women, with an estimated 15% to 36% of these patients dying within a year. A growing focus on holistic health and wellness promotes regular health screenings, including bone density assessments. As individuals increasingly monitor their bone health, early diagnosis and intervention become crucial, further driving market growth. The osteoporosis treatment market is significantly bolstered by heightened awareness of bone health, which fuels demand for both preventive and therapeutic solutions.

Segmental Analysis:

The analysis of the osteoporosis treatment market has been conducted by examining the following segments: drug class, type, route of administration, and distribution channel.

In terms of drug class, the osteoporosis treatment market is divided into RANKL inhibitors, bisphosphonates, selective estrogen receptor modulators (SERMs), hormone therapies, and others. The RANKL segment accounted for the largest market share in 2023, while the hormone therapies segment is projected to experience the highest CAGR from 2023 to 2031. The bisphosphonates segment also holds a significant share in the osteoporosis treatment market. Bisphosphonates, including alendronate and zoledronic acid, are effective in inhibiting bone resorption, enhancing bone density, and reducing fracture risk. Their extensive clinical history, regulatory approvals, and availability in both oral and intravenous forms make them a preferred choice among healthcare providers. Additionally, their cost-effectiveness and broad insurance coverage contribute to their widespread use in osteoporosis treatment.

The market is categorized by type into primary osteoporosis and secondary osteoporosis. The primary osteoporosis segment held a larger share of the osteoporosis treatment market in 2023. Primary osteoporosis is associated with aging, leading to a gradual decline in bone renewal. A study published in the National Library of Medicine titled "Prevalence of Primary Osteoporosis and Low Bone Mass in Postmenopausal Women and Associated Risk Factors" indicates that 30% of women over 50 globally have osteoporosis, with 8% to 9% of annual bone fractures attributed to this condition. Furthermore, men and women aged 70 and older experience an imbalance between bone formation and loss, resulting in back pain, diminished quality of life, and difficulties in daily activities.

Regarding the route of administration, the osteoporosis treatment market is divided into oral and injectable forms. The injectable segment held the largest market share in 2023 and is expected to register the highest CAGR from 2023 to 2031. The dominance of the injectable segment can be attributed to its effectiveness and reliability as a drug delivery method. Administering treatment via injections allows for direct entry of the drug into the bloodstream, ensuring rapid and predictable absorption, which is crucial in osteoporosis treatment. Additionally, some osteoporosis medications are exclusively available in injectable form, further enhancing this segment's market share. With improved patient compliance for self-administered injections and ongoing advancements in drug delivery technologies, the injectable segment is well-positioned to maintain its strong market presence.

Regional Analysis:The osteoporosis treatment market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North American market was valued at US$ 8.26 billion in 2023 and is projected to reach US$ 11.26 billion by 2031, with an expected CAGR of 3.9% during 2023 to 2031. A significant factor driving market growth in this region is the large aging population, coupled with increased awareness of osteoporosis. Additionally, advanced healthcare infrastructure and comprehensive access to medical services facilitate timely diagnosis and treatment. The presence of major pharmaceutical companies and ongoing research and development efforts are also fostering the introduction of innovative therapies. Furthermore, favorable reimbursement policies and insurance coverage support patients seeking osteoporosis treatment, thereby promoting market growth in North America.

The Asia Pacific osteoporosis treatment market is anticipated to achieve the highest CAGR of 4.7%. This region, particularly countries like India and China, boasts a substantial pharmaceutical industry, with China serving as a manufacturing hub. The projected growth in this region is driven by a burgeoning middle class and improved access to healthcare. Moreover, advancements in healthcare infrastructure and the emerging pharmaceutical sector position the Asia Pacific as a key area for significant growth and development in the osteoporosis treatment market.

Osteoporosis Treatment Market Report Scope Key Player Analysis:Key players profiled in the osteoporosis treatment market report include Pfizer Inc., Amgen Inc., Cadila Pharmaceuticals, Eli Lilly and Company, Daiichi Sankyo Company, Limited, Teva Pharmaceuticals Inc., Asahi Kasei Corporation, Novartis AG, Chugai Pharmaceutical Co., Ltd., and Teijin Pharma Limited.

Recent Developments:

Companies in the osteoporosis treatment market are employing mergers and acquisitions as primary growth strategies. Recent developments in the market include:

In October 2021, Entera Bio, a prominent biotechnology firm, announced significant data from its mid-stage oral osteoporosis drug formulation study, advancing to Phase 3 registration.In August 2021, the Drug Controller General of India (DCGI) granted Marketing Authorization (MA) to Enzene Biosciences Ltd for its biosimilar drug Denosumab, indicated for osteoporosis treatment in adults.In January 2021, Theramex, a London-based pharmaceutical company, launched the osteoporosis drug Livogiva in Europe.